Jennifer Taubert is Executive Vice President and Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, the world’s largest healthcare company. She is a member of the Corporation’s Executive Committee and leads the Pharmaceuticals Group Operating Committee.
Jennifer has been a leader in shaping the global strategy of transformational medical innovation for the Janssen Pharmaceutical Companies of Johnson & Johnson, successfully delivering vital new medicines for millions of people living with cancer, immune-related diseases, heart disease, pulmonary hypertension, infectious diseases and serious mental illness. Under her leadership, Janssen has become the second-largest innovative pharmaceutical business globally, with more than $50 billion in worldwide revenue. In addition, the company has been named No. 1 in the Pharmaceutical category on Fortune magazine’s “World’s Most Admired Companies” list for nine consecutive years.
Throughout her career, Jennifer has been committed to improving the lives of people with serious illnesses. Since joining Johnson & Johnson in 2005, her focus has been on reaching increasing numbers of patients around the world with the Company’s transformational therapies. Jennifer led global commercial strategy for the Pharmaceuticals Group and, later, as President, Internal Medicine, built a powerhouse new franchise in cardiovascular and metabolic disease. As Company Group Chairman, The Americas, the business doubled in size, outpacing the industry to become the No. 1 pharmaceutical company in the United States and Canada. Before joining Johnson & Johnson, Jennifer spent 17 years in positions of increasing scope and responsibility at Merck and Allergan.
In recognition of her impact on behalf of patients, Jennifer has been named to Fortune’s “Most Powerful Women” list for the past seven years. She was also named among the “100 Most Influential People in Healthcare” by Modern Healthcare magazine in 2020 and received the National Association for Female Executives’ 2017 “Woman of Achievement” award. Jennifer is also recognized as a leader in diversity, equity and inclusion, which she sees as critical to insight, innovation and business success.
Jennifer is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America, which represents the country’s leading innovative biopharmaceutical research companies, and she is Chair of the International Committee. She also serves on the National Academy of Medicine’s Leadership Consortium and on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. In addition, Jennifer is a member of the Board of Directors of McDonald’s Corporation.
Jennifer received a bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.
What is Jennifer L. Taubert's net worth?
The estimated net worth of Jennifer L. Taubert is at least $21.65 million as of February 9th, 2024. Ms. Taubert owns 141,416 shares of Johnson & Johnson stock worth more than $21,650,083 as of November 20th. This net worth approximation does not reflect any other assets that Ms. Taubert may own. Additionally, Ms. Taubert receives an annual salary of $3,100,000.00 as EVP at Johnson & Johnson. Learn More about Jennifer L. Taubert's net worth.
How old is Jennifer L. Taubert?
Ms. Taubert is currently 60 years old. There are 6 older executives and no younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Dr. John C. Reed M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, who is 66 years old. Learn More on Jennifer L. Taubert's age.
What is Jennifer L. Taubert's salary?
As the EVP of Johnson & Johnson, Ms. Taubert earns $3,100,000.00 per year. There are 2 executives that earn more than Ms. Taubert. The highest earning executive at Johnson & Johnson is Dr. John C. Reed M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, who commands a salary of $8,570,000.00 per year. Learn More on Jennifer L. Taubert's salary.
How do I contact Jennifer L. Taubert?
Has Jennifer L. Taubert been buying or selling shares of Johnson & Johnson?
Jennifer L. Taubert has not been actively trading shares of Johnson & Johnson over the course of the past ninety days. Most recently, Jennifer L. Taubert sold 59,397 shares of the business's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a transaction totalling $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company's stock, valued at $22,099,078.32. Learn More on Jennifer L. Taubert's trading history.
Who are Johnson & Johnson's active insiders?
Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.
Are insiders buying or selling shares of Johnson & Johnson?
During the last year, insiders at the sold shares 3 times. They sold a total of 68,757 shares worth more than $10,308,224.54. The most recent insider tranaction occured on August, 30th when VP Robert J Decker sold 5,635 shares worth more than $930,113.10. Insiders at Johnson & Johnson own 0.2% of the company.
Learn More about insider trades at Johnson & Johnson. Information on this page was last updated on 8/30/2024.